布地奈德缓释胶囊能有效治病吗？

Introduction: Budesonide sustained-release capsules are a drug used to treat primary immunoglobulin A nephropathy (IgAN) in adults. It can release budesonide when it reaches the intestine, thereby reducing the generation of defective IgA nephropathy, thereby reducing the accumulation of IgA nephropathy and damage to the kidneys.

Can the generic version of budesonide sustained-release capsules also be effective in treating diseases

In clinical trials, it has shown good efficacy. There are also generic versions, and regular generic drugs can also effectively treat IgA nephropathy. Generic drugs must pass strict bioequivalence testing to ensure they are equivalent in efficacy and safety to the original drugs. Generic drugs can also be considered effective if they pass these tests and are approved by regulatory agencies.

Patients should ensure that they obtain generic versions of budesonide extended-release capsules from legal and regulated channels to ensure the quality and safety of the drug and avoid buying counterfeit and substandard drugs.

Efficacy of Budesonide extended-release capsules

In a major study involving 364 patients with IgA nephropathy, after 9 months of treatment, patients taking budesonide extended-release capsules had a 34% reduction in proteinuria, compared with a 5% reduction in patients taking placebo. Long-term data showed that 15 months after the nine-month treatment period, proteinuria was reduced by 31% in patients treated with budesonide extended-release capsules, compared with a 1% reduction in patients treated with placebo.

Research data also show that budesonide extended-release capsules can slow down the decline of renal function, which can be seen from changes in estimated glomerular filtration rate (eGFR). A decrease in eGFR indicates renal function decline. After 15 months of the 9-month treatment period, patients receiving budesonide extended-release capsules had a decrease in eGFR of 7.5 ml/min/1.73m², while patients receiving placebo had a decrease in eGFR of 13.5 ml/min/1.73m².

How to take budesonide extended-release capsules

Patients should take budesonide extended-release capsules strictly according to the doctor's instructions. The recommended dose of the drug is 16 mg (four 4 mg capsules) once a day. Patients should take it at least 1 hour before meals in the morning and swallow it whole with a glass of water. The capsules have a special coating to ensure that the drug is released to the correct part of the intestine. Do not open, crush or chew the budesonide extended-release capsules to avoid affecting the release of the drug.

If you take more budesonide extended-release capsules than you should, consult your doctor or pharmacist immediately. Do not stop taking budesonide extended-release capsules without your doctor's consent.